AstraZeneca PLC (AZN)
Market Cap | 210.70B |
Revenue (ttm) | 45.81B |
Net Income (ttm) | 5.96B |
Shares Out | 3.10B |
EPS (ttm) | 1.91 |
PE Ratio | 35.77 |
Forward PE | 16.23 |
Dividend | $1.45 (2.14%) |
Ex-Dividend Date | Feb 22, 2024 |
Volume | 3,417,857 |
Open | 68.18 |
Previous Close | 68.26 |
Day's Range | 67.68 - 68.36 |
52-Week Range | 60.47 - 76.56 |
Beta | 0.17 |
Analysts | Buy |
Price Target | 81.67 (+20.55%) |
Earnings Date | Apr 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $81.67, which is an increase of 20.55% from the latest price.
News
AstraZeneca CEO Soriot on Pharmaceuticals in China
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of...
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation rad...
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.
AstraZeneca to cap US out-of-pocket costs for inhalers to $35
AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month f...
AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline
AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.
Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca
PARIS--(BUSINESS WIRE)-- #VC--Sofinnova Partners announced that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition.
AstraZeneca strikes $1 billion deal for rare-disease drug maker
AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals.
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 202...
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio
Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE® (budeso...
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows
AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro...
AstraZeneca Announed Further GBP200 Million Investment Announced to Expand Presence in Cambridge
The government also said AstraZeneca and the U.K. Health Security Agency plan to partner “to advance science for developing and evaluating vaccines.”
AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'
AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance Minis...
Renewable Thermal Collaborative Releases Case Study on the U.S. Renewable Natural Gas (RNG) Agreement between AstraZeneca and Vanguard Renewables
BOSTON--(BUSINESS WIRE)--The Renewable Thermal Collaborative recently released a case study on the first-of-its-kind partnership between AstraZeneca and Vanguard Renewables to enable the delivery of r...
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
TOKYO & MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN...
Judge rejects AstraZeneca's challenge to Medicare drug price negotiations
U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.
‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?
Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.
SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today a coll...
FibroGen regains rights to anemia drug from AstraZeneca
FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.
Sodexo and AstraZeneca extend their global partnership for a further 5 years.
Sodexo and AstraZeneca extend their global partnership for a further 5 years. Issy les Moulineaux, February 22, 2024 Sodexo reinforces its contract of Food and Facilities Management Services with Astr...
Positive lung cancer results show our strategy is working: AstraZeneca
Greg Rossi, senior vice president of oncology in Europe and Canada at AstraZeneca, discusses the company's three announcements on lung cancer drugs and treatments.
AstraZeneca's stock surges on FTSE 100 on Tagrisso approval
AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were up ...